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Persistence rate (%) was deﬁned as the number of days between
ﬁrst biologic prescription and last biologic encounter, divided by
365 and multiplied by 100. Two mutually exclusive cohorts
were deﬁned based on their persistence rates: patients with per-
sistence >=80% and patients with persistence <80%. Total
health care and medical costs were assessed during the study
period. Per patient per month (PPPM) costs were calculated.
Cost of adverse events could not be identiﬁed separately in this
analysis. A multivariate model was used to adjust for covariates
including age, gender, Charlson Co-morbidity Index (CCI), and
pre-index period health care costs. RESULTS: In all, 358
patients were included, 206 (57.5%) with a persistence rate
<80% and 152 (42.5%) with a persistence rate >=80%. Nearly
half were female and the mean age was 45.2 years. The higher
persistence cohort had lower PPPM medical costs ($359.54
versus $407.14) and total health care costs ($1541.56 versus
$2653.30) compared with the lower persistence cohort. Also,
the multivariate analysis indicated that after adjusting for the
confounding factors: age, gender, CCI, and pre-index period
health care costs, a higher persistence rate is signiﬁcantly asso-
ciated with lower total health care PPPM costs (P < 0.0001).
CONCLUSION: A higher persistence rate with anti-TNF
therapy is associated with lower health care costs. Future studies
to examine the impact of persistence with anti-TNF therapy
on clinical and humanistic outcomes in patients with PsA are
recommended.
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OBJECTIVES: On September 30, 2004, rofecoxib—a drug used
to treat inﬂammation—was voluntarily withdrawn from the US
market due to mounting evidence of increased cardiovascular
(CV) risk. This study sought to assess movement in the number
of clinically appropriate (CAP) cyclo-oxygenase (COX)-2
prescriptions dispensed after the rofecoxib withdrawal; and
whether patients with CAP proﬁles demonstrated different post-
withdrawal switching behavior or incurred different levels of
health care costs. METHODS: Administrative claims data from
four regional health plans were used. To examine differences in
clinically appropriate prescribing pre- and post-rofecoxib with-
drawal, a generalized estimating equations approach was used.
RESULTS: Based on a total of 317,762 prescriptions, this study
found that CAP prescribing rates were lower after news of the
increased drug risk, as were the total number of COX-2 prescrip-
tions that were clinically inappropriate. Patients with CAP risk
were more likely to exhibit switching behavior by ﬁlling prescrip-
tions for nonselective (ns) NSAIDs or discontinuing use of all
NSAIDs. Health care costs incurred in the year following the
rofecoxib withdrawal were lower for patients who were pre-
scribed COX-2s appropriately. CONCLUSION: These ﬁndings
suggest that the widespread coverage of the rofecoxib with-
drawal, which led to heightened awareness of the drug’s risk
affected consumer demand for COX-2s and may have had unin-
tended consequences in reducing the number of patients who
“should have been” receiving these medications according to
clinical risk. Because patients and physicians were forced to make
a medical decision under risk, increased information of the
beneﬁt-risk tradeoff may have been helpful and may have con-
tributed to greater consumer welfare.
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OBJECTIVES: Pharmacovigilance is a very important tool for
registration authorities and pharmaceutical industries to gather
extra information on effectiveness and adverse effects of widely
used drugs. Therefore, post-marketing research can lead to new
insights on therapeutic usability and consequently changes
in registration ﬁles or even result in market withdrawal. In
September 2004, rofecoxib was withdrawn from the market for
reasons of serious cardiovascular adverse events. Our objective
was to evaluate trends in market-share and expenditures of
cyclooxygenase-2 (cox-2) selective and non-selective NSAIDs
around market withdrawal of rofecoxib. METHODS: Analyses
were conducted using pharmacy prescription data from IADB.nl
(50 pharmacies), covering a Dutch population of 500,000 sub-
jects. NSAID-use was calculated per 10,000 of the population
and presented quarterly from 2000–2006. Expenditures related
to NSAID-use were calculated and presented in costs per 1000 of
the population. RESULTS: After market introduction of cox-2
selective NSAIDs, proportional use increased to a maximum of
17% in the third quarter of 2004. After market withdrawal of
rofecoxib, the number of subjects receiving celecoxib and etori-
coxib increased enormously (from 22 to 48 and 18 to 28 subjects
per 10,000 population, respectively), but decreased shortly there-
after. Similar results were found for new users. After market
withdrawal, costs per 1000 population decreased with 65% and
24% for cox-2 selective and the total group of NSAIDs, respec-
tively. During additional study follow-up, costs per DDD were
generally increasing for cox-2 selective and decreasing for other
NSAIDs. Further results will be presented on switching patterns
from rofecoxib to other NSAIDs, with a speciﬁc focus on con-
comitant use of proton-pump-inhibitors for gastrointestinal pro-
tection and related extra costs. CONCLUSION: Withdrawal of
rofecoxib from the Dutch market resulted in a decreasing
number of subjects receiving cox-2 selective NSAIDs (class-
effect) and lower expenditures for the whole group of NSAIDs.
Further research is currently conducted to complete the full eco-
nomic picture.
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OBJECTIVES: The pharmacological prescription can present
geographical variation due to multiple factors. The aim of this
communication is to introduce the spatial variability in the evalu-
ation of different individual outcomes. METHODS: Pharmaco-
logical prescription data of 10,410 persons with diagnosis of
osteoarthrosis were analyzed. The prescriptions were fulﬁlled
during the year 2006 in the health department 11 of the Comu-
nitat Valenciana (Spain). The number of recipes, the number of
prescribed principles and the pharmaceutical expense for every
patient were evaluated. The relationship with gender and age was
explored by means of generalized linear models. The geographi-
cal variation between different administrative units is introduced
by means of heterogeneity and structured random effects. The
proposed hierarchical models were analyzed using Bayesian
methods with MCMC procedures. RESULTS: Models with
random spatial effects explain an important part of the variabil-
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